A Nature Biotechnology paper reports that mRNA vaccine efficacy can be enhanced by bioorthogonal-like delayed activation of an exogenous STING adjuvant. The approach aims to separate timing between antigen expression and innate immune activation to strengthen antitumor responses. The study, published online August 19, 2026, describes a delayed STING triggering mechanism paired with mRNA vaccination, with the goal of improving how immune pathways are engaged while reducing premature or mistimed activation. (STING is a cytosolic pathway that helps drive type I interferon responses.) For vaccine developers, the results highlight continued momentum toward adjuvant engineering and temporal control as a lever to increase potency across solid tumors and difficult-to-treat settings.